Immunis
Developer of stem cell-derived therapy designed to treat age and disease-related immune decline. The company's technology uses human stem cells for clinical use and directs them to become pure populat...
Valuation
$75M
Market implied
Share Price
N/A
Total Raised
$37M
Last Round
N/A